Obsidian Therapeutics

Executive Summary

Obsidian Therapeutics is a private biotechnology company developing next-generation controllable cell therapies for oncology, leveraging its proprietary cytoDRiVE® platform to precisely regulate therapeutic protein expression. The platform aims to enhance the efficacy and safety of tumor-infiltrating lymphocyte (TIL) and CAR-T therapies by enabling tunable control of protein expression, potentially reducing toxicity and improving persistence. Founded in 2015 and headquartered in Cambridge, MA, the company has raised $160M to advance its pipeline into Phase 1 clinical trials. Obsidian's approach addresses key limitations of current cell therapies, such as on-target off-tumor toxicity and limited durability, by employing a small molecule 'switch' to control the timing and level of therapeutic protein activity. The company is well-positioned in the competitive cell therapy landscape, with a strong intellectual property portfolio and experienced management team. While still early-stage, Obsidian's differentiated technology could unlock broader applicability of cell therapies in solid tumors, representing a compelling opportunity for investors seeking exposure to innovative oncology platforms.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 clinical data readout for lead TIL therapy30% success
• Q2 2026Potential partnership or licensing deal for cytoDRiVE platform40% success
• Q4 2026New Series C funding round or strategic investment50% success